Navigation Links
OptiNose's novel intranasal sumatriptan product highly effective in treating migraines
Date:4/7/2010

Oslo, April 7, 2010: OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.

Sumatriptan powder in 10mg and 20mg doses administered intranasally using OptiNose's bi-directional delivery device was highly effective in treating a single attack of moderate or severe migraine. The proportion of patients pain-free at two hours was 54% for the 10 mg dose, 57% for 20 mg and 25% for placebo (P< .05). These results compare very favorably with published figures of 26-42% for liquid sumatriptan nasal spray and 35.6% for zolmitriptan nasal spray and higher than the 28% /29% reported for oral triptans. In addition to high efficacy, OptiNose's bi-directional powder delivery eliminates drip-out and reduces the bitter taste associated with conventional nasal triptan products.

The proportion of subjects with relief of headache post-dose was significantly greater than placebo at 60 minutes (10 mg 73% vs. 38%, P< .01; 20 mg 74% vs. 38%, P< .01), 90 minutes (10 mg 78% vs. 41%, P< .01; 20 mg 77% vs. 41%, P< .01) and 120 minutes (10 mg 84% vs. 44%, P< .001; 20 mg 80% vs. 44%, P< .01). The onset of pain relief was much quicker than conventional orally and nasally delivered triptans and similar to subcutaneous injection of sumatriptan despite much lower systemic exposure. Sustained pain-freedom at 48 hours was also high for both doses (10 mg 47%, 20 mg 49%, P < .05). Treatment-related adverse events were rare.

"The World Health Organization places migraine amongst the top 20 of disabling disorders from a global perspective," says Fred Sheftell, M.D., founder and director of the New England Center for Headache in Stamford, CT. "Novel delivery systems that deliver rapid and sustained pain relief with minimal side effects are needed. The results of this study are encouraging and suggest that a novel formulation of an already established efficacious agent in the acute therapy of migraine via a novel and user friendly device could benefit many migraine patients."

"We are extremely encouraged by these results", says Dr. Per Djupesland, the study's co-author and CSO at OptiNose. "This study confirms that the superior deposition and rapid absorption of OptiNose's sumatriptan product offers both early and prolonged relief from pain without undesirable side effects. We are convinced that our treatment will provide unique advantages to patients with this debilitating disease."


'/>"/>

Contact: Helena Djupesland
Helena.Djupesland@optinose.no
01-147-229-58017
WFD Ventures
Source:Eurekalert

Related biology news :

1. UMMS researchers uncover novel genetic pathway responsible for triggering vascular growth
2. Novel Parkinsons treatment strategy involves cell transplantation
3. New University of Colorado paper shows novel way to study human inflammatory disease
4. Novel antitoxin strategy developed using tagged binding agents
5. Intelligent people have unnatural preferences and values that are novel in human evolution
6. Novel studies of decomposition shed new light on our earliest fossil ancestry
7. Linheng Li proposes novel theory for mammalian stem cell regulation
8. GE Healthcare to evaluate and develop novel imaging technology
9. Novel nanotechnology heals abscesses caused by resistant staph bacteria
10. H1N1 influenza adopted novel strategy to move from birds to humans
11. Lupus Research Institute announces 2009 novel research grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... ... is a basic first aid supply for any work environment, but most personal eye wash ... if a dangerous substance enters both eyes? It’s one less decision, and likely quicker response ... piece. , “Whether its dirt and debris, or an acid or alkali, getting anything in ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... ... , ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled ... bold new look is part of a transformation to increase awareness, appeal to new ... , It will also expand its service offering from its signature gourmet cooking classes ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
Breaking Biology Technology: